secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCorRx Inc. (BICX)
CIK:        0001443863
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001477932-25-001603
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCorRx acquires FDA-approved opioid withdrawal drug Lucemyra from USWM LLC
----------------------------------------------------------------------------

- Upfront purchase price of $400,000 paid via seller retention of 50% of net sales and net distributable profits until capped.
- BioCorRx issued 500,000 shares of common stock and a warrant for 500,000 shares at $1.00 exercise price, 2-year term.
- Lucemyra is first and only non-opioid FDA-approved medication for opioid withdrawal; BioCorRx expects meaningful sales and positive cash flow.
- BioCorRx will pay a low single-digit royalty to USWM on future sales; no direct cash payment at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1443863/000147793225001603/0001477932-25-001603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1443863/000147793225001603/bicx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-001603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer